Follicular Toxic Effects of Chimeric Anti-Epidermal Growth Factor Receptor Antibody Cetuximab Used to Treat Human Solid Tumors

Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab

“…However, it has also been suggested that EGF-R has a role in follicular physiology and consequently significant cutaneous toxic effects has been found in cancer patients treated with similar compounds. [14][15][16] Unexpectedly, we have not found any cutaneous side-effect in monkeys treated with the anti-EGF-R Nimotuzumab; this result agrees with clinical findings in which follicular effect was not found either. 8 Nimotuzumab has not demonstrated any toxic cutaneous effect in numerous clinical trials, even though its clinical benefit was equivalent or superior to other similar anti epidermal growth factor monoclonal antibodies.…”

Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab

“…However, it has also been suggested that EGF-R has a role in follicular physiology and consequently significant cutaneous toxic effects has been found in cancer patients treated with similar compounds. [14][15][16] Unexpectedly, we have not found any cutaneous side-effect in monkeys treated with the anti-EGF-R Nimotuzumab; this result agrees with clinical findings in which follicular effect was not found either. 8 Nimotuzumab has not demonstrated any toxic cutaneous effect in numerous clinical trials, even though its clinical benefit was equivalent or superior to other similar anti epidermal growth factor monoclonal antibodies.…”

Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients

“…The hair follicle changes are frequent but not the most typical histopathologic picture of EPPE, as reported in literature . According to our experience, perifolliculis (43.6%) is more common than neutrophilic folliculitis (28.2%) and it is supported mainly by lymphocytes.…”

Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys

“…The humanized h-R3 mAb binds EGF-R, blocking its signal transduction pathway, causing internalization and downregulation of transmembrane EGF-R, but it has also been suggested that EGF-R has a role in follicular physiology and significant cutaneous toxic effects have been found in cancer patients treated with similar compounds. 14 We have not found any cutaneous side effect in monkeys treated with the anti-EGF-R mAb h-R3. This result agrees with clinical findings in which no follicular effect was found in cancer patients treated with the murine or humanized mAb.…”

Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab

“…However, it has also been suggested that EGF-R has a role in follicular physiology and consequently significant cutaneous toxic effects has been found in cancer patients treated with similar compounds. [14][15][16] Unexpectedly, we have not found any cutaneous side-effect in monkeys treated with the anti-EGF-R Nimotuzumab; this result agrees with clinical findings in which follicular effect was not found either. 8 Nimotuzumab has not demonstrated any toxic cutaneous effect in numerous clinical trials, even though its clinical benefit was equivalent or superior to other similar anti epidermal growth factor monoclonal antibodies.…”

Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients

“…The hair follicle changes are frequent but not the most typical histopathologic picture of EPPE, as reported in literature . According to our experience, perifolliculis (43.6%) is more common than neutrophilic folliculitis (28.2%) and it is supported mainly by lymphocytes.…”

Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys

“…The humanized h-R3 mAb binds EGF-R, blocking its signal transduction pathway, causing internalization and downregulation of transmembrane EGF-R, but it has also been suggested that EGF-R has a role in follicular physiology and significant cutaneous toxic effects have been found in cancer patients treated with similar compounds. 14 We have not found any cutaneous side effect in monkeys treated with the anti-EGF-R mAb h-R3. This result agrees with clinical findings in which no follicular effect was found in cancer patients treated with the murine or humanized mAb.…”

Systemic and skin toxicity in cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab

“…However, it has also been suggested that EGF-R has a role in follicular physiology and consequently significant cutaneous toxic effects has been found in cancer patients treated with similar compounds. [14][15][16] Unexpectedly, we have not found any cutaneous side-effect in monkeys treated with the anti-EGF-R Nimotuzumab; this result agrees with clinical findings in which follicular effect was not found either. 8 Nimotuzumab has not demonstrated any toxic cutaneous effect in numerous clinical trials, even though its clinical benefit was equivalent or superior to other similar anti epidermal growth factor monoclonal antibodies.…”

Histopathologic features of erythematous papulopustular eruption to epidermal growth factor receptor inhibitors in cancer patients

“…The hair follicle changes are frequent but not the most typical histopathologic picture of EPPE, as reported in literature . According to our experience, perifolliculis (43.6%) is more common than neutrophilic folliculitis (28.2%) and it is supported mainly by lymphocytes.…”

Multiple dose toxicity study of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 intravenously administered to Cercopithecus aethiops sabaeus monkeys

“…The humanized h-R3 mAb binds EGF-R, blocking its signal transduction pathway, causing internalization and downregulation of transmembrane EGF-R, but it has also been suggested that EGF-R has a role in follicular physiology and significant cutaneous toxic effects have been found in cancer patients treated with similar compounds. 14 We have not found any cutaneous side effect in monkeys treated with the anti-EGF-R mAb h-R3. This result agrees with clinical findings in which no follicular effect was found in cancer patients treated with the murine or humanized mAb.…”